Investors want to know whether Eli Lilly is seeing the same pricing pressures on its blockbuster weight loss drug Zepbound that Novo Nordisk experienced with its…
Stocks had a rough week, topped off with a pummeling Friday after the July jobs data came in weaker than expected. The Nasdaq led the way…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Brendan McDermid | ReutersAll doses of Eli…
10 things to watch Friday, July 19 Can tech stocks and the overall market stabilize to end the week? That’s what to watch after a brutal…
Federal Trade Commission Chair Lina Khan testifies during a hearing of the House Appropriations Subcommittee on Financial Services and General Government, May 15, 2024.Tom Williams |…
(This is CNBC Pro’s live coverage of Wednesday’s analyst calls and Wall Street chatter. Please refresh every 20-30 minutes to view the latest posts.) Tesla and…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. U.S.…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. U.S.…
Novo Nordisk’s new manufacturing facility in Clayton, North Carolina.Courtesy: Novo NordiskNovo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant…
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects…